Scribd
Upload
54 views

Final Report SWOT Analysis PDF

This startup is developing a drug to slow the progression of Alzheimer's disease by reducing the production of beta-amyloid protein in the brain. The founders have published promising research and their phase 1 and 2 drug trials showed the drug is safe and effective. However, the startup is running low on funding and does not have any other drug candidates in their pipeline if the initial drug fails testing. They aim to improve their research on monitoring brain structures and signals associated with Alzheimer's and hope to sell the company once phase 3 trials are complete. The document recommends investing in the startup due to the massive potential market and rewards, despite risks from a lack of funding and pipeline drugs.

Uploaded by

Rebeca RL
Copyright
© © All Rights Reserved
Available Formats
Download as PDF, TXT or read online on Scribd
54 views

Final Report SWOT Analysis PDF

This startup is developing a drug to slow the progression of Alzheimer's disease by reducing the production of beta-amyloid protein in the brain. The founders have published promising research and their phase 1 and 2 drug trials showed the drug is safe and effective. However, the startup is running low on funding and does not have any other drug candidates in their pipeline if the initial drug fails testing. They aim to improve their research on monitoring brain structures and signals associated with Alzheimer's and hope to sell the company once phase 3 trials are complete. The document recommends investing in the startup due to the massive potential market and rewards, despite risks from a lack of funding and pipeline drugs.

Uploaded by

Rebeca RL
Copyright
© © All Rights Reserved
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 2

Paulina Guzmán Lira

& Rebeca Rovirosa Limón


English Advanced 1
Juan José Gómez Guerrero

Biometrics

Background
This is a start-up with some origins in academia. Their PhD founders created
Biotech. They have developed a website to showcase their concept. Together they
are developing a drug that slows progression of Alzheimers by slowing production of
beta-amyloid, an associated protein with the disease. To get better results, they are
doing more research as their lab is the world leader in the field. Perhaps they have to
do more study as everyone reacts differently to the drugs. They are looking to
improve the lives of people suffering from Alzheimer's.
Swot

Strengths Weaknesses
Ceo/CFO are external hires Running out of cash
Page 1 trials passed Lack of other drugs in pipeline
Phase 2 looking good

Opportunities Threads
Gap in the marking ageing population Other labs doing similar research

Report
The three founders are ambitious in looking to improve the research they already
have. Meanwhile they are examining the changes in brain structure and electrical
signals that are accompanying the onset AD by using the brains printing biometrics.
They are researching another technique that monitorates brain structures and
waves. Their exit strategy is to sell their shares to a large pharmaceutical company.
Somehow this should be easy when phase 3 is reached.
There are a couple of strengths: The Operations of the entire company (CEO) and
the Chief Financial officer (CEO) are the ones appointing the first round funding. The
phase 1 trial showed that the drug was safe, and phase 2 showed that the drug's
effectiveness is very promising. And a big strength from our point of view is that
there are no other drugs in the market.
There are two weaknesses. First, there is a high probability of their funding running
out, they only have enough funds to work for 3 months more. The Three Founders
seem like they don’t have their own capital to keep on with the research. The second
issue is that there are no other drugs in the pipeline, which means there aren't other
options if their initial drug fails the tests. In case this happens I don’t think the
research could be sustained, that means you would be losing your money.

The opportunities here are endless as currently there is not a successful treatment
for Alzheimer in the market. With 5% to 8% of adults worldwide suffering from this
terrible disease, the potential market for a treatment or cure is massive. On the other
hand if they reach the perfect formula it would be easy to sell. However this disease
is only treatable the drug would have to be for lifetime, this means the clients would
be clients until they pass away.

Recommendation
My recommendation is yes, we should invest in this product. Not only can it be a
huge help for our world, but also a huge financial opportunity. While there are
certainly some risks to the investment, the potential reward is worthy of the risk.

You might also like